Fatigue and thinking problems after allogeneic stem cell transplant (synapse damage or brain GVHD)
Fatigue Och Kognitiv Dysfunktion Till följd av Synaptopati Eller Graft Versus Host (GVH) Sjukdom i hjärnan.
This project uses PET scans and spinal fluid samples to try to find why people who had an allogeneic stem cell transplant have persistent fatigue and thinking problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 20 Years to 75 Years |
| Sex | All |
| Sponsor | Karolinska University Hospital Academic / other |
| Locations | 1 site (Stockholm) |
| Trial ID | NCT07365696 on ClinicalTrials.gov |
What this trial studies
Patients who undergo allogeneic stem cell transplantation at Karolinska are followed in the outpatient clinic and offered systematic measurement of fatigue and cognitive impairment using international standards. As part of the program, cerebrospinal fluid samples and advanced PET imaging are collected or reviewed to study immune and structural changes in the brain. The project is observational and includes retrospective PET images where available. Data will be used for combined immunological and radio‑morphological analyses to link symptoms with biological markers.
Who should consider this trial
Good fit: Ideal candidates are adults who received an allogeneic stem cell transplant, report persistent fatigue or cognitive symptoms, and have PET imaging and/or cerebrospinal fluid samples available through Karolinska follow-up.
Not a fit: People who did not have an allogeneic transplant, who lack PET images or spinal-fluid samples, or who have no fatigue or cognitive complaints are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this work could identify imaging or spinal-fluid markers that help diagnose causes of post-transplant fatigue and cognitive dysfunction and guide more targeted care.
How similar studies have performed: Previous PET and cerebrospinal-fluid studies have detected neuroinflammation and synaptic changes in related conditions, but applying these markers specifically to post-transplant GVHD-related cognitive problems is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: PET images available retrospectively
Where this trial is running
Stockholm
- Ksenia Boriskina — Stockholm, Sweden (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.